Roche licenses sefaxersen from Ionis Pharmaceuticals

Roche has licensed sefaxersen from Ionis Pharmaceuticals to develop and potentially commercialize the therapy for complement-mediated diseases. The drug candidate was evaluated in the phase III IMAgINATION study (NCT05797610).

Detected & updated continuously · Source: Nebula